OAM
BCLI

Oxford Asset Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Oxford Asset Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-925
Closed -$57K – 1621
2017
Q3 		$57K Buy
+925
New +$59.9K ﹤0.01% 1495

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oxford Asset Management's BCLI Position: Q4 2017 in Review

Oxford Asset Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2017, closing a stake of 925 shares — an estimated $57K sold.

Oxford Asset Management first reported a position in BCLI in Q3 2017 and held it in 1 quarter. The position peaked at $57K in Q3 2017. 35 funds tracked by Wall St. Rank hold BCLI as of Q4 2017.

  • Oxford Asset Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2017 after selling out during the quarter.
  • Oxford Asset Management sold 925 BRAINSTORM CELL THERAPUTC shares in Q4 2017, an estimated $57K.
  • Oxford Asset Management first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2017 and held it in 1 quarter.
  • Oxford Asset Management's BRAINSTORM CELL THERAPUTC position peaked at $57K in Q3 2017.
  • 35 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2017.

Based on Oxford Asset Management's 13F filing for Q4 2017, filed 13 Feb 2018.